Matches in SemOpenAlex for { <https://semopenalex.org/work/W1502727202> ?p ?o ?g. }
Showing items 1 to 62 of
62
with 100 items per page.
- W1502727202 endingPage "8" @default.
- W1502727202 startingPage "1105" @default.
- W1502727202 abstract "A phase I trial of fazarabine (ara-AC, 1-beta-D-arabinofuranosyl-5-azacytosine, NSC 281272) administered as a 24-h continuous infusion was performed in 24 adults with solid tumor malignancies. The majority of patients had received prior marrow-suppressive therapy. Level 7 (54.5 mg/m2/h for 24 h) was the maximum tolerated dose since during 6 evaluable first courses, 2 episodes of grade 4 granulocytopenia and 3 episodes of grade 3 occurred. Moderate thrombocytopenia also occurred at level 7 with 3 episodes of grade 1 and 1 episode of grade 4 thrombocytopenia during 6 first course treatments. Minimal myelosuppression, principally leukopenia, was seen prior to level 7. The nadir WBC through 47 courses had a linear relationship with plasma steady-state concentrations of ara-AC. The only other toxicity noted was moderate nausea/vomiting, which did not appear to be dose related. Plasma steady-state concentrations of ara-AC were reached in all patients within 4-6 h and ranged from 1.1 microM (11 mg/m2/h for 24 h) to 7.5 microM (54.5 mg/m2/h for 24 h). The mean total body clearance of ara-AC for 47 courses, levels 1-7, was 592 +/- 147 (SD) ml/min/m2 which is similar to prior pharmacokinetic data from the 24-h and 72-h infusion trials of the Pediatric and Medicine Branches, respectively. There were no objective disease responses during the trial. The recommended adult phase II dose for a 24-h infusion of ara-AC is 45-50 mg/m2/h." @default.
- W1502727202 created "2016-06-24" @default.
- W1502727202 creator A5016030632 @default.
- W1502727202 creator A5021727848 @default.
- W1502727202 creator A5037903114 @default.
- W1502727202 creator A5061697254 @default.
- W1502727202 creator A5071045353 @default.
- W1502727202 creator A5085166459 @default.
- W1502727202 creator A5091632652 @default.
- W1502727202 date "1991-02-15" @default.
- W1502727202 modified "2023-09-23" @default.
- W1502727202 title "Phase I clinical trial of fazarabine as a twenty-four-hour continuous infusion." @default.
- W1502727202 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1705165" @default.
- W1502727202 hasPublicationYear "1991" @default.
- W1502727202 type Work @default.
- W1502727202 sameAs 1502727202 @default.
- W1502727202 citedByCount "6" @default.
- W1502727202 crossrefType "journal-article" @default.
- W1502727202 hasAuthorship W1502727202A5016030632 @default.
- W1502727202 hasAuthorship W1502727202A5021727848 @default.
- W1502727202 hasAuthorship W1502727202A5037903114 @default.
- W1502727202 hasAuthorship W1502727202A5061697254 @default.
- W1502727202 hasAuthorship W1502727202A5071045353 @default.
- W1502727202 hasAuthorship W1502727202A5085166459 @default.
- W1502727202 hasAuthorship W1502727202A5091632652 @default.
- W1502727202 hasConcept C112705442 @default.
- W1502727202 hasConcept C126322002 @default.
- W1502727202 hasConcept C2780580376 @default.
- W1502727202 hasConcept C2780852908 @default.
- W1502727202 hasConcept C2780873365 @default.
- W1502727202 hasConcept C29730261 @default.
- W1502727202 hasConcept C71924100 @default.
- W1502727202 hasConcept C90924648 @default.
- W1502727202 hasConceptScore W1502727202C112705442 @default.
- W1502727202 hasConceptScore W1502727202C126322002 @default.
- W1502727202 hasConceptScore W1502727202C2780580376 @default.
- W1502727202 hasConceptScore W1502727202C2780852908 @default.
- W1502727202 hasConceptScore W1502727202C2780873365 @default.
- W1502727202 hasConceptScore W1502727202C29730261 @default.
- W1502727202 hasConceptScore W1502727202C71924100 @default.
- W1502727202 hasConceptScore W1502727202C90924648 @default.
- W1502727202 hasIssue "4" @default.
- W1502727202 hasLocation W15027272021 @default.
- W1502727202 hasOpenAccess W1502727202 @default.
- W1502727202 hasPrimaryLocation W15027272021 @default.
- W1502727202 hasRelatedWork W141775729 @default.
- W1502727202 hasRelatedWork W1980701009 @default.
- W1502727202 hasRelatedWork W2074629895 @default.
- W1502727202 hasRelatedWork W2079580408 @default.
- W1502727202 hasRelatedWork W2400113917 @default.
- W1502727202 hasRelatedWork W2411797564 @default.
- W1502727202 hasRelatedWork W2417803418 @default.
- W1502727202 hasRelatedWork W2434503764 @default.
- W1502727202 hasRelatedWork W2460981146 @default.
- W1502727202 hasRelatedWork W2468000090 @default.
- W1502727202 hasVolume "51" @default.
- W1502727202 isParatext "false" @default.
- W1502727202 isRetracted "false" @default.
- W1502727202 magId "1502727202" @default.
- W1502727202 workType "article" @default.